Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics.
10.3348/kjr.2017.18.5.809
- Author:
Jeong Sub LEE
1
;
Se Hyung KIM
;
Seock Ah IM
;
Min A KIM
;
Joon Koo HAN
Author Information
1. Department of Radiology, Jeju National University Hospital, Jeju 63241, Korea.
- Publication Type:Original Article
- Keywords:
Stomach;
Cancer;
HER2 status;
CT
- MeSH:
Epidermal Growth Factor*;
Humans*;
Liver;
Logistic Models;
Methods;
Neoplasm Metastasis;
Prevalence;
Receptor, Epidermal Growth Factor*;
Retrospective Studies;
Stomach;
Stomach Neoplasms*
- From:Korean Journal of Radiology
2017;18(5):809-820
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To retrospectively analyze the qualitative CT features that correlate with human epidermal growth factor receptor 2 (HER2)-expression in pathologically-proven gastric cancers. MATERIALS AND METHODS: A total of 181 patients with pathologically-proven unresectable gastric cancers with HER2-expression (HER2-positive [n = 32] and negative [n = 149]) were included. CT features of primary gastric and metastatic tumors were reviewed. The prevalence of each CT finding was compared in both groups. Thereafter, binary logistic regression determined the most significant differential CT features. Clinical outcomes were compared using Kaplan-Meier method. RESULTS: HER2-postive cancers showed lower clinical T stage (21.9% vs. 8.1%; p = 0.015), hyperattenuation on portal phase (62.5% vs. 30.9%; p = 0.003), and was more frequently metastasized to the liver (62.5% vs. 32.2%; p = 0.001), than HER2-negative cancers. On binary regression analysis, hyperattenuation of the tumor (odds ratio [OR], 4.68; p < 0.001) and hepatic metastasis (OR, 4.43; p = 0.001) were significant independent factors that predict HER2-positive cancers. Median survival of HER2-positive cancers (13.7 months) was significantly longer than HER2-negative cancers (9.6 months) (p = 0.035). CONCLUSION: HER2-positive gastric cancers show less-advanced T stage, hyperattenuation on the portal phase, and frequently metastasize to the liver, as compared to HER2-negative cancers.
